The products are awaiting for inspection by health authorities due to a proprietary step in Aurora’s production process, the publication said. Until the review is complete, the products will remain unavailable.
The pharmacies reportedly said the production step in question is connected to a method that Aurora uses to protect the shelf life of the flower.
The company “stands behind the safety of products previously sold to medical patients and has not initiated a recall,” an Aurora spokesperson told Marijuana Business Daily.
“Products for the German market are sourced from an EU GMP (Good Manufacturing Process)-certified facility and are safe to consume.”
Aurora projects that German sales will resume “very early in the new year.”
Even if the interruption is short, it could create undesirable consequences for the company, as patients who already use Aurora's product will have to switch to another supplier.
If and when Aurora’s product sales commence again, patients would need a new prescription, and doctors are known to be reluctant about prescribing products with inconsistent availability, according to Marijuana Business Daily.
Aurora shares were trading 1.23% higher at $2.47 at the time of publication Tuesday.
Aurora's CBD Oil Approved As Medical Marijuana Product In Ireland
Aurora Cannabis Analyst Says Company Poised To Outperform Canadian Peers
Photo courtesy of Aurora Cannabis.
See more from Benzinga
- Aurora's CBD Oil Approved As Medical Marijuana Product In Ireland
- Aurora Cannabis Analyst Says Company Poised To Outperform Canadian Peers
- Aurora Cannabis Promotes 2 Execs, Says 94% Of Holders Chose To Convert Debentures
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.